The funny thing is none of us here invested in IME for the FDA approval. It really wasn't even a factor.
We invested in IME because of its current strong revenues and growth within South America and Asia/Pacific. It was and is still cheap in relation to this alone.
But interestingly FDA approval for RHT has added around $33m to RHTs MC alone. When this comes for IME I expect we'll move well over 10c quite easily.
The funny thing is none of us here invested in IME for the FDA...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
